RPL21P116

Across TCGA pan-cancer cohorts, RPL21P116 RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated RPL21P116 data layer.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher RPL21P116 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RPL21P116 expression acts as an unfavorable survival marker, although some lineages such as STAD and HNSC show a favorable association.

OV, LUSC, and UVM are the cancer types where RPL21P116 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Quartile	II,III,IV	0.597	0.713	.001	46	view →
LUSC	DFS	Quartile	III,IV	0.274	0.816	.008	12	view →
UVM	OS	Median	III,IV	0.468	0.931	.009	10	view →
STAD	OS	Median	IV	0.539	0.206	.011	9	view →
ACC	OS	Median	IV	0.466	0.818	.011	9	view →
HNSC	DFS	Median	IV	0.566	0.334	.021	9	view →
THCA	OS	Median	III,IV	1.000	0.916	.019	7	view →
KIRC	OS	Tertile	All	0.922	0.881	.013	6	view →
UCS	DFS	Median	III,IV	0.559	0.286	.030	6	view →
CESC	OS	Quartile	II,III,IV	0.936	0.668	.010	6	view →
MESO	OS	Median	All	0.477	0.297	.015	6	view →
KIRP	OS	Tertile	All	0.892	0.979	.012	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

RPL21P116–OV (OS)

Open the OV breakdown →